Galapagos NV ADR Total Liabilities
Galapagos NV ADR total liabilities. Based on the latest financial reports, Galapagos NV ADR (GLPG) has total liabilities worth $119.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Galapagos NV ADR (GLPG) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Galapagos NV ADR (2004–2025)
Total liabilities of Galapagos NV ADR from 2004 to 2025. This chart illustrates how Galapagos NV ADR's total liabilities have evolved over time, based on quarterly financial data. Explore Galapagos NV ADR (GLPG) investment intensity to see how much of total assets are deployed in long-term investments.
Galapagos NV ADR Competitors by Total Liabilities
The table below lists competitors of Galapagos NV ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Palvella Therapeutics, Inc
NASDAQ:PVLA
|
USA | $36.58 Million |
|
Stolt-Nielsen Limited
OL:SNI
|
Norway | Nkr3.29 Billion |
|
Sinbon Electronics Co Ltd
TW:3023
|
Taiwan | NT$15.50 Billion |
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
Canada | CA$2.83 Billion |
|
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
|
Vietnam | ₫859.26 Trillion |
|
Horace Mann Educators Corporation
NYSE:HMN
|
USA | $14.10 Billion |
|
Sparebank 1 Nord-Norge
OL:NONG
|
Norway | Nkr124.99 Billion |
|
Jangho Group Co Ltd
SHG:601886
|
China | CN¥20.87 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Galapagos NV ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Galapagos NV ADR assets under control.
Liquidity & Leverage Metrics
Galapagos NV ADR Total Liabilities Ratios Explained
Galapagos NV ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos NV ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos NV ADR (2004–2025)
The table below shows the annual total liabilities of Galapagos NV ADR from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.58 Million | -86.23% |
| 2024-12-31 | $1.24 Billion | -20.68% |
| 2023-12-31 | $1.56 Billion | -29.28% |
| 2022-12-31 | $2.21 Billion | -13.39% |
| 2021-12-31 | $2.55 Billion | -16.33% |
| 2020-12-31 | $3.05 Billion | -4.56% |
| 2019-12-31 | $3.19 Billion | +1317.53% |
| 2018-12-31 | $225.25 Million | -17.88% |
| 2017-12-31 | $274.29 Million | -15.51% |
| 2016-12-31 | $324.64 Million | +318.81% |
| 2015-12-31 | $77.52 Million | +20.49% |
| 2014-12-31 | $64.33 Million | -46.50% |
| 2013-12-31 | $120.24 Million | +2.87% |
| 2012-12-31 | $116.88 Million | +173.86% |
| 2011-12-31 | $42.68 Million | -6.11% |
| 2010-12-31 | $45.45 Million | +30.49% |
| 2009-12-31 | $34.83 Million | +0.96% |
| 2008-12-31 | $34.50 Million | -31.13% |
| 2007-12-31 | $50.10 Million | -13.78% |
| 2006-12-31 | $58.10 Million | +184.45% |
| 2005-12-31 | $20.43 Million | +289.38% |
| 2004-12-31 | $5.25 Million | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more